{"id":391695,"date":"2014-04-04T00:00:00","date_gmt":"2014-04-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0214-biopharma-breast-cancer-triple-negative-advanced-metastatic-decision-base-us-2014\/"},"modified":"2026-04-24T11:33:15","modified_gmt":"2026-04-24T11:33:15","slug":"dbason0214-biopharma-breast-cancer-triple-negative-advanced-metastatic-decision-base-us-2014","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0214-biopharma-breast-cancer-triple-negative-advanced-metastatic-decision-base-us-2014\/","title":{"rendered":"Breast Cancer (Triple-Negative, Advanced\/Metastatic) | Decision Base | US | 2014"},"content":{"rendered":"<p><em>What attributes will distinguish emerging therapies in the eyes of oncologists and payers?<\/em><\/p>\n<p>Treatment options for triple-negative breast cancer patients are limited, as patients are ineligible for treatment with either hormonal or HER2-targeted agents. Treatment typically involves nontargeted cytotoxic chemotherapies. Therefore, great commercial opportunity exists in developing effective, targeted therapies for this patient population. Interviewed oncologists are hopeful that more-effective targeted therapies are on the horizon for this patient population. However, the most promising emerging agents in development for triple-negative breast cancer target only specific subsets of patients, such as those with <em>BRCA1\/2<\/em>-mutation positive disease. As a result, the majority of the triple-negative breast cancer population is likely to remain underserved for the foreseeable future.<\/p>\n","protected":false},"template":"","class_list":["post-391695","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391695\/revisions"}],"predecessor-version":[{"id":394818,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391695\/revisions\/394818"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}